Diabetic kidney disease remains the most common cause of end-stage renal disease, indicating the need for additional therapeutic approaches beyond renin–angiotensin system blockade. Here, the authors review developments in renoprotective therapy in the past decade and critically analyse failed randomized controlled trials. They also discuss novel approaches to diabetic kidney disease that have shown promise in animal models or are currently being investigated in clinical studies.
- Beatriz Fernandez-Fernandez
- Alberto Ortiz
- Jesus Egido
